source
- Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't wantMadrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…Endpoints · 2mo ago↗ source
- Healthcare organizations are increasingly building their own AI toolsBig healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…Endpoints · 2mo ago↗ source
- Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in MyelofibrosisAndrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.